Amylyx Pharmaceuticals, Inc.
AMLX
株式のランク
#4246
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
株価
$29.32
最終同期: 2026-10-21
時価総額
$3.68B
変化（1日）
1.91%
変化（1年）
97.84%
国
US
取引 Amylyx Pharmaceuticals, Inc. (AMLX)
カテゴリー
Healthcare
Amylyx Pharmaceuticals, Inc.（AMLX）の株価履歴
終値の最高値: $27.68 （2026-10-01）
終値の最安値: $19.75 （2022-01-01）
終値の最安値: $19.75 （2022-01-01）
Amylyx Pharmaceuticals, Inc. の株価履歴（2022 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 41.29% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $760.40 | 8.08% |
CH
|
